SCHEMBL2948910

SCHEMBL2948910

O=C(O)CC(c1ccccc1)c1ccc(OCCCC(F)(F)F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.54
POLB P06746 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HDAC1 Q13547 3/20 0.46
HDAC2 Q92769 3/20 0.46
PPARA Q07869 1/20 0.45
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13236690 0.85 TDP1 (0.46) FFAR1TDP1SMN1; SMN2PPARA
SCHEMBL2947112 0.83 FFAR1 (0.60) FFAR1POLBTDP1L3MBTL1SMN1; SMN2
SCHEMBL2948148 0.82 FFAR1 (0.68) FFAR1POLBTDP1L3MBTL1SMN1; SMN2
SCHEMBL2946000 0.80 FFAR1 (0.60) FFAR1POLBTDP1L3MBTL1SMN1; SMN2
SCHEMBL2941508 0.80 MMP9 (0.65) FFAR1POLBTDP1L3MBTL1SMN1; SMN2
SCHEMBL2947981 0.80 SMN1; SMN2 (0.74) FFAR1POLBTDP1L3MBTL1SMN1; SMN2
SCHEMBL2949131 0.79 MMP9 (0.67) FFAR1POLBTDP1L3MBTL1SMN1; SMN2
SCHEMBL2939695 0.79 MMP9 (0.67) FFAR1POLBTDP1L3MBTL1SMN1; SMN2
SCHEMBL2949666 0.78 FFAR1 (0.62) FFAR1POLBTDP1L3MBTL1SMN1; SMN2
SCHEMBL22800008 0.78 FFAR1 (0.65) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US claimed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US claimed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-7750048-B2 GPR40 agonists JANSSEN PHARMACEUTICA NV (BE) 2010-07-06 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed
US-20080176912-A1 GPR40 AGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176912-A1 GPR40 AGONISTS GPR119, GPR65, GPR55 FFAR1 8/4885POLB 4593/4885TDP1 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.